Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000947871-26-000190·CytomX Therapeutics, Inc.
Schedule 13G ownership disclosure
CytomX Therapeutics Inc
Common Stock, par value $0.00001 per share · CUSIP: 23284F105
Event date: 2025-12-31
- Filing-level shares
- 3,525,650.00
- Percent of class
- 2.1%
- OrbiMed Advisors LLC
Shares: 3,525,650.00 · Class: 2.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-26-000190
- Form type
- SCHEDULE 13G/A
- Filer
- CytomX Therapeutics, Inc.
- CIK
- CIK 1501989
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership